24/7 Market News Snapshot 02 April, 2025 – Hoth Therapeutics, Inc. Common Stock (NASDAQ:HOTH)

April 2, 2025

DENVER, Colo., 02 April, 2025 (247marketnews.com) – (NASDAQ:HOTH) are discussed in this article.
Hoth Therapeutics, Inc. (HOTH) is witnessing a positive movement in the stock market with its shares trading at $1.003, marking a 2.90% increase from the previous close of $0.975. This surge reflects heightened buying interest and optimism among investors, as indicated by a trading volume of 3.20 million shares, showcasing active market engagement. Analysts suggest that if the stock maintains its momentum and closes above resistance levels around $1.10, it may further affirm the bullish trend observed in the pre-market session.

In addition to its stock performance, Hoth Therapeutics announced a significant collaboration with a renowned medical research institution to advance research targeting Alzheimer’s disease. This project aims to evaluate HT-ALZ, an FDA-approved NK-1 receptor antagonist, for its potential to reduce neuroinflammation and alleviate cognitive impairment associated with the disease. The initiative is being led by a distinguished professor known for her contributions to the fields of Psychiatry, Neurology, and Neuroscience.

The research involves a comprehensive grant proposal submitted to the National Institutes of Health (NIH), titled “Cell Type Specificity of Neurokinin-1 Receptor Antagonists on Cognitive Improvement.” It seeks to unravel the specific cellular mechanisms that make HT-ALZ effective in improving cognitive function and addressing neuroinflammatory responses. Preliminary studies have shown that chronic administration of HT-ALZ leads to notable enhancements in cognitive performance and significant reductions in anxiety-like behaviors, alongside a decrease in brain interstitial fluid Aβ40 levels.

Robb Knie, the CEO of Hoth Therapeutics, emphasized the importance of this partnership, stating that it represents a critical development in exploring the therapeutic potential of NK-1 receptor antagonism for neurological disorders. By providing GMP-quality HT-ALZ for research, Hoth Therapeutics aims to uphold high standards in preclinical investigations, potentially offering new hope to the millions impacted by Alzheimer’s disease.

Related news for (HOTH)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.